CONSORT flowchart of participants. by Vanessa Wellauer (18408477)

“…</p><p>Trial registration number</p><p>NCT04902924 (ClinicalTrials.gov), SNCTP000004468 (Swiss National Clinical Trial Portal).…”

Basic characteristics of the studies included. by Renáta Kiss-Miki (20760127)

Subjects:

PRISMA flowchart of the article selection process. by Renáta Kiss-Miki (20760127)

Subjects:

List_of_studies_identified_31-JAN-2025. by Renáta Kiss-Miki (20760127)

Subjects:

Forest plot showing the mean difference of global IQ level among pediatric brain cancer patients treated with either PT or XRT. by Renáta Kiss-Miki (20760127)

Subjects:

Forest plot showing the ratio of odds of hypothyroidism (=event) among pediatric brain cancer patients treated with either PT or XRT. by Renáta Kiss-Miki (20760127)

Subjects:

Forest plot showing the ratio of odds of acute side effects: nausea (a) and vomiting (b) (=events) among pediatric patients with brain tumors treated with PT or XRT. by Renáta Kiss-Miki (20760127)

Subjects:

Forest plot showing the odds of 5-year overall-survival rate among children with brain tumors treated with either PT or XRT. by Renáta Kiss-Miki (20760127)

Subjects:

Data_table_with_all_identified_articles_31-JAN-2025. by Renáta Kiss-Miki (20760127)

Subjects:

Data_extraction_table_31-JAN-2025. by Renáta Kiss-Miki (20760127)

Subjects:

Forest plot showing the ratio of odds of grade 3 anemia (=event) among pediatric patients with brain tumors treated with either PT or XRT. by Renáta Kiss-Miki (20760127)

Subjects:

Receiver operating characteristic curve analyses for the prediction of hepatitis C. by Lu Han (151620)

Subjects:

Effects of bevacizumab addition on VEGF-A concentrations <i>in vitro</i>. by Masashi Okawa (8951294)

Subjects:

Uronic acid analysis-based screen identified IFA as an effective capsule inhibitor. by Tingting Wang (123983)

Subjects:

IFA did not affect LPS-induced inflammation response. by Tingting Wang (123983)

Subjects:

IFA reduced the capsular biosynthesis through altering bacterial metabolism. by Tingting Wang (123983)

Subjects:

Effect of adding rhVEGF-A (-121 or -165) on the concentrations of VEGF-A121 and VEGF-A165 in plasma samples. by Masashi Okawa (8951294)

Subjects:

IFA abrogated capsule-associated hypermucoviscosity phenotypes of hypervirulent <i>K</i>. <i>pneumoniae</i>. by Tingting Wang (123983)

Subjects:

Exploring the correlation between systemic inflammation biomarkers and HCV infection (logarithm base 2). by Lu Han (151620)

Subjects:

Effect of the VEGF-A–bevacizumab complex removal using immunoprecipitation on the concentrations of VEGF-A121, VEGF-A165, and VEGF-A. by Masashi Okawa (8951294)

Subjects: